The CBER Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics (BEST 3)

The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), has awarded a Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ) contract for the Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics. This initiative establishes a network of data sources to support the surveillance of biologics, classified under NAICS 518210 for Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services and PSC B537 for Special Studies/Analysis- Medical/Health. Each contract features a $50,000,000 ceiling and a $10,000 minimum guarantee for performance occurring within the United States.

The FDA Office of Acquisition and Grant Services finalized three awards under solicitation number FDA-SOL-1224068. The Lewin Group, Inc. received contract 75F40120D00026 on September 30, 2020, while IQVIA Government Solutions, Inc. (75F40120D00027) and AETNA INC. / Healthagen LLC (75F40120D00028) received their awards on September 29, 2020. Suzanne Martella serves as the point of contact for this award notice, which was published on October 5, 2020.